Skip to main content

Table 2 Significantly affected pathways by HDMTX treatment

From: Metabolic profiling reveals metabolic features of consolidation therapy in pediatric acute lymphoblastic leukemia

Pathways

P

−Log(p)

FDR

Impact

Pyrimidine metabolism

0.0087

2.0600

0.65

0.09

Phenylalanine, tyrosine, and tryptophan biosynthesis

0.0154

1.8100

0.65

0.50

Phenylalanine metabolism

0.0382

1.4200

1.00

0.36

Arginine biosynthesis

0.0531

1.2800

1.00

0.23

Pantothenate and CoA biosynthesis

0.0714

1.1500

1.00

0.00

Beta-alanine metabolism

0.0787

1.1000

1.00

0.00

Fatty acid degradation

0.1420

0.8480

1.00

0.00

Aminoacyl-tRNA biosynthesis

0.1720

0.7640

1.00

0.00

  1. Metabolic pathways with P < 0.05 were considered significantly altered